chronic lymphocytic leukaemia

News

Filmmaker helps AbbVie spread the word about leukaemia

AbbVie has turned to an award-winning documentary director to help it highlight the lives of people living with chronic lymphocytic leukaemia.

News

Lilly eyes earlier use of blood cancer drug Jaypirca

Lilly's fast-growing blood cancer drug Jaypirca could gain more momentum thanks to a trial suggesting it could move into the first-line setting.

News

AbbVie files to move Venclexta combo into the CLL front line

AbbVie has filed for FDA approval of a new front-line therapy for chronic lymphocytic leukaemia that it thinks could be 'practice changing."

News

AZ claims EU approval for new Calquence regimens in CLL

AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, currently facing a strong challenge from BeOne's rival Brukinsa.

News

AMPLIFY results dial up Calquence's potential in CLL

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuste

News

NICE says yes to J&J, AbbVie first-line leukaemia regimen

Patients in England with chronic lymphocytic leukaemia (CLL) will be able to access a new combination therapy based on Johnson & Johnson’s Imbruvica plus AbbVie’s Venc

Filmmaker helps AbbVie spread the word about leukaemia

Lilly eyes earlier use of blood cancer drug Jaypirca

AbbVie files to move Venclexta combo into the CLL front line

AZ claims EU approval for new Calquence regimens in CLL

AMPLIFY results dial up Calquence's potential in CLL

NICE says yes to J&J, AbbVie first-line leukaemia regimen

Ex-BioNTech execs launch 'AI-native' cancer company

Discover a new era of healthcare panel engagement: Grounded ...

chronic lymphocytic leukaemia

Editor's Picks